论文部分内容阅读
目的观察多西紫杉醇为主的联合方案治疗晚期乳腺癌的疗效及不良反应。方法晚期乳腺癌患者52例中,35例既往使用蒽环类治疗失败,予多西紫杉醇联合顺铂化疗或多西紫杉醇联合希罗达化疗,17例既往未曾采用蒽环类治疗,予多西紫杉醇联合表阿霉素化疗。21天为1周期,2周期后评价疗效,有效者化疗6周期。结果52例中CR6例,PR28例,SD10例,PD8例,总有效率为65.4%(34/52)。中位疾病进展进间(TTP)8.2个月,中位生存时间(MST)17.6个月。不良反应主要为骨髓抑制、消化道反应及脱发,但均可耐受,无化疗相关死亡。结论多西紫杉醇为主的联合化疗方案治疗晚期乳腺癌疗效较好,不良反应可耐受。
Objective To observe the efficacy and adverse reactions of docetaxel-based combination regimen in the treatment of advanced breast cancer. Methods Of the 52 patients with advanced breast cancer, 35 patients had failed previous anthracycline treatment with docetaxel plus cisplatin or docetaxel combined with Xeloda. 17 patients who had never received anthracycline therapy before, Paclitaxel combined with epirubicin chemotherapy. 21 days for the 1 cycle, 2 cycles after the evaluation of efficacy, the effective chemotherapy 6 cycles. Results Among 52 cases, CR6, PR28, SD10 and PD8 had a total effective rate of 65.4% (34/52). The median progression to progression (TTP) was 8.2 months, and the median survival time (MST) was 17.6 months. Adverse reactions are mainly myelosuppression, gastrointestinal reactions and hair loss, but are tolerable, without chemotherapy-related deaths. Conclusions Docetaxel-based combination chemotherapy is effective in treating advanced breast cancer, and adverse reactions are tolerable.